A screen capture from a Kalderos video about its 340B Pay software platform that enables drug manufacturers to pay 340B ceiling prices as rebates instead of as discounts.
Bipartisan Group of 217 U.S. Representatives Ask HHS to Stop 340B Rebate Model and Look Into Third Party Vendors
Two hundred seventeen U.S. representatives—173 Democrats and 44 Republicans—this morning asked U.S. Health and Human Services (HHS) Secretary Alex Azar to take immediate action to stop drug companies and a vendor from changing the 340B program from a discount to a rebate model.
Lawmakers told Azar in a Nov. 13 letter that pharma information technology company Kalderos’ 340B Pay software unilaterally forces 340B participants to buy drugs at list price and then request rebates, giving drug manufacturers “tremendous leverage over covered entities.”